Summary | |
---|---|
Symbol | BGN |
Name | biglycan |
Aliases | DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Secreted, extracellular space, extracellular matrix |
Domain |
PF13855 Leucine rich repeat PF01462 Leucine rich repeat N-terminal domain |
Function |
May be involved in collagen fiber assembly. |
Biological Process |
GO:0001933 negative regulation of protein phosphorylation GO:0001974 blood vessel remodeling GO:0006022 aminoglycan metabolic process GO:0006023 aminoglycan biosynthetic process GO:0006024 glycosaminoglycan biosynthetic process GO:0006026 aminoglycan catabolic process GO:0006027 glycosaminoglycan catabolic process GO:0006029 proteoglycan metabolic process GO:0006469 negative regulation of protein kinase activity GO:0006790 sulfur compound metabolic process GO:0007259 JAK-STAT cascade GO:0009100 glycoprotein metabolic process GO:0009101 glycoprotein biosynthetic process GO:0018149 peptide cross-linking GO:0018209 peptidyl-serine modification GO:0019800 peptide cross-linking via chondroitin 4-sulfate glycosaminoglycan GO:0030166 proteoglycan biosynthetic process GO:0030198 extracellular matrix organization GO:0030203 glycosaminoglycan metabolic process GO:0030204 chondroitin sulfate metabolic process GO:0030205 dermatan sulfate metabolic process GO:0030206 chondroitin sulfate biosynthetic process GO:0030207 chondroitin sulfate catabolic process GO:0030208 dermatan sulfate biosynthetic process GO:0033673 negative regulation of kinase activity GO:0042326 negative regulation of phosphorylation GO:0043062 extracellular structure organization GO:0044272 sulfur compound biosynthetic process GO:0044273 sulfur compound catabolic process GO:0046425 regulation of JAK-STAT cascade GO:0046426 negative regulation of JAK-STAT cascade GO:0048771 tissue remodeling GO:0050650 chondroitin sulfate proteoglycan biosynthetic process GO:0050651 dermatan sulfate proteoglycan biosynthetic process GO:0050654 chondroitin sulfate proteoglycan metabolic process GO:0050655 dermatan sulfate proteoglycan metabolic process GO:0051348 negative regulation of transferase activity GO:0097696 STAT cascade GO:1901136 carbohydrate derivative catabolic process GO:1901565 organonitrogen compound catabolic process GO:1902532 negative regulation of intracellular signal transduction GO:1903510 mucopolysaccharide metabolic process GO:1904892 regulation of STAT cascade GO:1904893 negative regulation of STAT cascade |
Molecular Function |
GO:0004857 enzyme inhibitor activity GO:0004860 protein kinase inhibitor activity GO:0005201 extracellular matrix structural constituent GO:0005539 glycosaminoglycan binding GO:0019207 kinase regulator activity GO:0019210 kinase inhibitor activity GO:0019887 protein kinase regulator activity GO:0050840 extracellular matrix binding |
Cellular Component |
GO:0005578 proteinaceous extracellular matrix GO:0005775 vacuolar lumen GO:0005796 Golgi lumen GO:0030133 transport vesicle GO:0042383 sarcolemma GO:0043202 lysosomal lumen |
KEGG | - |
Reactome |
R-HSA-1971475: A tetrasaccharide linker sequence is required for GAG synthesis R-HSA-2024101: CS/DS degradation R-HSA-2022870: Chondroitin sulfate biosynthesis R-HSA-1793185: Chondroitin sulfate/dermatan sulfate metabolism R-HSA-4420332: Defective B3GALT6 causes EDSP2 and SEMDJL1 R-HSA-3560801: Defective B3GAT3 causes JDSSDHD R-HSA-3560783: Defective B4GALT7 causes EDS, progeroid type R-HSA-3595174: Defective CHST14 causes EDS, musculocontractural type R-HSA-3595172: Defective CHST3 causes SEDCJD R-HSA-3595177: Defective CHSY1 causes TPBS R-HSA-2022923: Dermatan sulfate biosynthesis R-HSA-1643685: Disease R-HSA-3560782: Diseases associated with glycosaminoglycan metabolism R-HSA-3781865: Diseases of glycosylation R-HSA-3000178: ECM proteoglycans R-HSA-1474244: Extracellular matrix organization R-HSA-1630316: Glycosaminoglycan metabolism R-HSA-1638091: Heparan sulfate/heparin (HS-GAG) metabolism R-HSA-1430728: Metabolism R-HSA-71387: Metabolism of carbohydrates |
Summary | |
---|---|
Symbol | BGN |
Name | biglycan |
Aliases | DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between BGN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between BGN and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | BGN |
Name | biglycan |
Aliases | DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of BGN in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | BGN |
Name | biglycan |
Aliases | DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of BGN in various data sets.
|
Points in the above scatter plot represent the mutation difference of BGN in various data sets.
|
Summary | |
---|---|
Symbol | BGN |
Name | biglycan |
Aliases | DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BGN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | BGN |
Name | biglycan |
Aliases | DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BGN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BGN. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | BGN |
Name | biglycan |
Aliases | DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BGN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | BGN |
Name | biglycan |
Aliases | DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of BGN expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | BGN |
Name | biglycan |
Aliases | DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between BGN and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | BGN |
Name | biglycan |
Aliases | DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ...... |
Chromosomal Location | Xq28 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting BGN collected from DrugBank database. |
There is no record. |